Color Atlas of Liver Pathology. By R. S. Patrick. 175 pp. New York: Oxford University Press, 1983. $75.
Adrianne E. Rogers – 1 January 1983
Non‐A, Non‐B Hepatitis
Jack R. Wands – 1 January 1983
Nuclear Magnetic Resonance and the Future of Hepatology
Irwin M. Arias – 1 January 1983
Application of Nuclear Magnetic Resonance to the Study of Liver Physiology and Disease
Sheila M. Cohen – 1 January 1983
Immunological Aspects of Chronic Active Hepatitis
Ian R. Mackay – 1 January 1983
Diagnostic Effectiveness of Serum Bile Acids in Liver Diseases as Evaluated by Multivariate Statistical Methods
Davide Festi, Antonio Maria Morselli Labate, Aldo Roda, Franco Bazzoli, Roberto Frabboni, Paola Rucci, Francesco Taroni, Rita Aldini, Enrico Roda, Luigi Barbara – 1 January 1983 – The aims of this study were to determine the diagnostic effectiveness of fasting and postprandial serum bile acid determinations in liver diseases, and to compare results with those of conventional liver function tests.
A Prospective Randomized Study of Two Sclerotherapy Techniques for Esophageal Varices
David Westaby, Brian R. D. Macdougall, Walter Melia, Andrew Theodossi, Roger Williams – 1 January 1983 – In a study designed to compare the efficacy and safety of two techniques of injection sclerotherapy, 40 patients (30 with cirrhosis and 10 with portal vein block) were randomly allocated to the sheath or free‐hand technique. Although the former was associated with significantly less bleeding within the first 24 hr of injection (p < 0.05) but more postinjection pain (p < 0.05) and esophageal stricture, there was a trend toward earlier obliteration of varices.
Analysis of Liver Disease, Nuclear HBcAg, Viral Replication, and Hepatitis B Virus DNA in Liver and Serum of HBcAg Vs. Anti‐HBe Positive Carriers of Hepatitis B Virus
Stephanos J. Hadziyannis, Harvey M. Lieberman, Gerassimos G. Karvountzis, David A. Shafritz – 1 January 1983 – Nine HBeAg+ and 24 anti‐HBe+ subjects with chronic hepatitis B virus (HBV) infection were studied for HBV DNA in the serum by molecular hybridization, for HBeAg in the liver by immunofluorescence, and for histologic evidence of liver disease.
Ultrastructural Evidence of Intrahepatic Cholestasis Before and After Chenodeoxycholic Acid Therapy in Patients with Cholelithiasis: The National Cooperative Gallstone Study
M. James Phillips, Rosemarie L. Fisher, Deborah W. Anderson, Shu‐Ping Lan, John M. Lachin, James L. Boyer, The Steering Committee for the National Cooperative Gallstone Study Group – 1 January 1983 – Electron microscopy was performed to assess potential hepatotoxicity before and after 9 and 24 months of chenodeoxycholic acid (CDCA) therapy (375 or 750 mg, daily) in 103 patients with cholelithiasis.